Effect of cimicifuga racemosa on menopausal syndrome caused by LHRH-a in breast cancer

Cimicifuga racemose is previously proved effective on nature menopausal syndrome (MPS). However, its clinical value in treating with MPS induced by luteinizing-hormone releasing hormone analogue (LHRH-a) therapy of pre-/peri-menopausal breast cancer patients is still unknown. This perspective random...

Full description

Saved in:
Bibliographic Details
Published in:Journal of ethnopharmacology 2019-06, Vol.238, p.111840-111840, Article 111840
Main Authors: Wang, Chen, Huang, Qiang, Liang, Chen-Lu, Zhang, Yi-Wen, Deng, De-Hou, Yu, Yang, Chen, Dao-Bao, Yang, Hong-Jian, Yu, Xing-Fei
Format: Article
Language:English
Subjects:
Adult
Breast cancer
Breast Neoplasms - drug therapy
Cimicifuga
Cimicifuga racemosa
Female
Gonadotropin-Releasing Hormone - adverse effects
Humans
Luteinizing-hormone releasing hormone analogue
Menopause syndrome
Menopause, Premature - drug effects
Phytotherapy
Plant Extracts - therapeutic use
Syndrome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cimicifuga racemose is previously proved effective on nature menopausal syndrome (MPS). However, its clinical value in treating with MPS induced by luteinizing-hormone releasing hormone analogue (LHRH-a) therapy of pre-/peri-menopausal breast cancer patients is still unknown. This perspective randomised-design study is to investigate the effect and safety of cimicifuga racemosa on MPS induced by LHRH-a in breast cancer (clinical trial registered: NCT03339882). Breast cancer patients planning for LHRH-a treatment were randomly divided into 2 groups. The control group which was being treated with the standard treatment of LHRH-a. The other group was being treated with Remifemin, the commercialized product of cimicifuga racemose extract, combined with LHRH-a, called Remifemin group. Our main endpoint was Kupperman menopause index (KMI). Hormone levels in peripheral blood and gynecological complications were also evaluated. Totally, 85 patients (42 in Remifemin group and 43 in control group) were enrolled in Zhejiang Cancer Hospital. At the 4th, 8th and 12th week after using LHRH-a, the KMI were all significantly lower in Remifemin group than in control group (P  0.05). Cimicifuga racemose is effective, oncological safe and reliable for treatment of MPS caused by LHRH-a in breast cancer. [Display omitted]
ISSN:0378-8741
1872-7573
DOI:10.1016/j.jep.2019.111840